News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AxoGen, Inc. (AXGN) To Present At Canaccord Genuity Musculoskeletal Conference


3/3/2014 1:11:08 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ALACHUA, FL – March 3, 2014 – AxoGen, Inc. (NASDAQ: AXGN), the only company completely focused on peripheral nerve repair, is scheduled to present at the 9th Annual Canaccord Genuity Musculoskeletal Conference on Tuesday, March 11, 2014 at 11:10am CT (12:10pm ET) at the Sheraton New Orleans Hotel.

A live webcast and subsequent archived replay of the Company’s presentation may be accessed via the Investor section of the Company’s website, http://ir.axogeninc.com/ .

About AxoGen, Inc.

Founded in 2002, AxoGen (NASDAQ: AXGN) is the only medical technology company focused on peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several European countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation. To receive email alerts directly from AxoGen, please click here

http://www.axogeninc.com/emailalerts.html.

Source: AxoGen, Inc.
Contact:
AxoGen, Inc.
Greg Freitag, Chief Financial Officer & General Counsel
386.462.6856
InvestorRelations@AxoGenInc.com

EVC Group
Bob Jones/Michael Polyviou – Investor Relations
646.201.5447/212.850.6020
bjones@evcgroup.com; mpolyviou@evcgroup.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES